| Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application. | |
| | |
MedLine Citation:
|
PMID: 19329672 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The purpose of this study was to examine the therapeutic potential of ranolazine, a novel antianginal drug, as an adjunctive therapy to hyperkalemic cardioplegia. Rat hearts were Langendorff-perfused and exposed to 40 minutes of ischemia and 30 minutes of reperfusion without (control) or with cardioplegia or cardioplegia with 50 micromol/L ranolazine. During ischemia, cardioplegia prolonged time to contracture, defined as the time to reach an intraventricular pressure of 20 mm Hg, from 12 +/- 1 minute (control) to 25 +/- 2 minutes (P < .05). Ranolazine supplement further lengthened the time to contracture to 34 +/- 2 minutes (P < .05). Ischemia/reperfusion caused a dramatic elevation in left ventricular end diastolic pressure (LVEDP) during reperfusion. Cardioplegia lessened the LVEDP elevation measured at 30 minutes of reperfusion from 76 +/- 3 mm Hg (control) to 32 +/- 3 mm Hg (P < .05). The increase in LVEDP was reduced even further to 17 +/- 2 mm Hg in hearts receiving cardioplegia plus ranolazine (P < .05). These results suggest that addition of ranolazine during hyperkalemic ischemic cardioplegic arrest is beneficial and provides further protection against contracture. |
| | |
Authors:
|
Hyosook Hwang; Joseph M Arcidi; Sharon L Hale; Boris Z Simkhovich; Luiz Belardinelli; Arvinder K Dhalla; John C Shryock; Robert A Kloner |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-03-27 |
Journal Detail:
|
Title: Journal of cardiovascular pharmacology and therapeutics Volume: 14 ISSN: 1074-2484 ISO Abbreviation: J. Cardiovasc. Pharmacol. Ther. Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-05-22 Completed Date: 2009-07-09 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9602617 Medline TA: J Cardiovasc Pharmacol Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 125-33 Citation Subset: IM |
Affiliation:
|
Heart Institute, Good Samaritan Hospital, Los Angeles, California 90017, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetanilides
/
administration & dosage,
pharmacology* Animals Blood Pressure Cardioplegic Solutions / therapeutic use* Cardiovascular Agents / administration & dosage, pharmacology* Female Heart Arrest, Induced / methods* Myocardial Reperfusion Injury / physiopathology, prevention & control Piperazines / administration & dosage, pharmacology* Rats Rats, Sprague-Dawley |
| Chemical | |
Reg. No./Substance:
|
0/Acetanilides; 0/Cardioplegic Solutions; 0/Cardiovascular Agents; 0/Piperazines; 110445-25-5/ranolazine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: p130 Crk-associated substrate (CAS) in vascular smooth muscle.
Next Document: Greenhouse gas fluxes in an eastern corn belt soil: weather, nitrogen source, and rotation.